Loading
A phase 2/3 trial testing Trabedersen in pancreatic ductal adenocarcinoma, now recruiting.
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer is a phase 2/3 interventional study registered as NCT06079346, led by Oncotelic, and recruiting on the registry. Official title: A Randomised Phase 2b/Phase 3 Study of the TGF-β2 Targeting Antisense Oligonucleotide OT-101 in Combination With mFOLFIRINOX Compared With mFOLFIRINOX Alone in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer. Planned enrolment is 455 participants (estimated). The study started in 2024-05-01 and primary completion is expected in 2026-06-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/